Picard Medical, Inc. (PMI) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Picard Medical, Inc. stock (PMI) is currently trading at $0.99. Picard Medical, Inc. PS ratio (Price-to-Sales) is 17.78. WallStSmart rates PMI as Sell.
- PMI PE ratio analysis and historical PE chart
- PMI PS ratio (Price-to-Sales) history and trend
- PMI intrinsic value — DCF, Graham Number, EPV models
- PMI stock price prediction 2025 2026 2027 2028 2029 2030
- PMI fair value vs current price
- PMI insider transactions and insider buying
- Is PMI undervalued or overvalued?
- Picard Medical, Inc. financial analysis — revenue, earnings, cash flow
- PMI Piotroski F-Score and Altman Z-Score
- PMI analyst price target and Smart Rating
Picard Medical, Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Picard Medical, Inc. (PMI) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth. Concerns around market cap and operating margin. Significant fundamental concerns warrant caution or avoidance.
Picard Medical, Inc. (PMI) Key Strengths (1)
Revenue surging 34.70% year-over-year
Picard Medical, Inc. (PMI) Areas to Watch (5)
Losing money on operations
Very expensive at 17.8x annual revenue
Very expensive at 10.6x book value
Very low institutional interest at 0.58%
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Picard Medical, Inc. (PMI) Detailed Analysis Report
Overall Assessment
This company scores 19/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 1 register as strengths (avg 10.0/10) while 5 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth. Growth metrics are encouraging with Revenue Growth at 34.70%.
The Bear Case
The primary concerns are Operating Margin, Price/Sales, Price/Book. Some valuation metrics including Price/Sales (17.78), Price/Book (10.64) suggest expensive pricing. Profitability pressure is visible in Operating Margin at -293.80%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Operating Margin improves, as this is the primary drag on the overall score. Second, margin trajectory, with Operating Margin at -293.80% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 34.70% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Operating Margin and Price/Sales are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
PMI Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
PMI's Price-to-Sales ratio of 17.78x sits near its historical average of 17.6x (50th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 7% below its historical high of 19.02x set in Mar 2026, and 7% above its historical low of 16.54x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Picard Medical, Inc. (PMI) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Picard Medical, Inc. is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 5M with 35% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Revenue growing at 35% YoY, reaching 5M. This pace significantly outperforms most MEDICAL DEVICES peers.
Spending 20% of revenue (951,000) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -7M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Picard Medical, Inc. maintain 35%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Picard Medical, Inc..
Bottom Line
Picard Medical, Inc. is a high-conviction growth story with revenue accelerating at 35% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 8:25:31 AM
About Picard Medical, Inc.(PMI)
NYSE MKT
HEALTHCARE
MEDICAL DEVICES
USA
Picard Medical, Inc., engages in the designing, manufacturing, production, supply, marketing, and sale of medical device products.